Meridian Bioscience market cap is $741.3 m, and annual revenue was $201.01 m in FY 2019

Meridian Bioscience Gross profit (Q3, 2020)55.9 M

Meridian Bioscience Gross profit margin (Q3, 2020), %65.9%

Meridian Bioscience Net income (Q3, 2020)27.5 M

Meridian Bioscience EBIT (Q3, 2020)34.7 M

Meridian Bioscience Cash, 30-Jun-202063.4 M

Meridian Bioscience EV783.4 M

Meridian Bioscience revenue was $201.01 m in FY, 2019

USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 26.6m | 26.8m | 33.4m | 38.0m | 34.7m | 35.5m | 32.2m | 21.6m | 23.8m | 24.4m |

## Depreciation and Amortization | 3.1m | 5.9m | 6.6m | 5.6m | 5.6m | 5.2m | 6.6m | 8.1m | 7.9m | 10.0m |

## Accounts Receivable | (4.4m) | (2.3m) | ||||||||

## Inventories | (1.1m) | 3.8m | ||||||||

## Accounts Payable | 4.1m | (2.3m) | ||||||||

## Cash From Operating Activities | 31.2m | 22.5m | 42.4m | 44.4m | 38.3m | 42.8m | 37.2m | 41.4m | 34.8m | 35.8m |

## Purchases of PP&E | (4.6m) | (9.1m) | (3.5m) | (3.2m) | (5.3m) | (4.6m) | (4.0m) | (4.5m) | (4.2m) | (3.8m) |

## Cash From Investing Activities | (17.8m) | (9.2m) | (4.4m) | (3.3m) | (7.0m) | (3.6m) | (66.7m) | (4.5m) | (4.2m) | (48.5m) |

## Long-term Borrowings | (1.5m) | (3.7m) | (4.5m) | (50.2m) | ||||||

## Dividends Paid | (30.0m) | (30.9m) | (31.2m) | (31.4m) | (32.8m) | (33.4m) | (33.6m) | (24.3m) | (21.2m) | (10.6m) |

## Cash From Financing Activities | (29.2m) | (27.5m) | (30.7m) | (28.6m) | (31.8m) | (30.7m) | 27.2m | (27.7m) | (27.6m) | 15.3m |

## Net Change in Cash | (16.2m) | (14.3m) | 8.0m | 12.7m | (1.2m) | 6.9m | (2.7m) | 9.8m | 2.7m | 1.6m |

## Interest Paid | 879.0k | 1.6m | 1.5m | |||||||

## Income Taxes Paid | 16.0m | 18.0m | 16.0m | 20.1m | 20.0m | 20.2m | 17.9m | 12.6m | 6.6m |

USD | Q3, 2010 |
---|---|

## Financial Leverage | 1.1 x |